WASHINGTON – The drug industry is quietly troubled over Donald Trump’s tough talk on trade. The Republican presidential nominee has promised to aggressively renegotiate America’s trade deals – and to tear them up if need be. Those pledges are now rankling a biopharmaceutical sector that depends heavily on the deals to protect their intellectual property and,…